Use of immunoglobulin against hepatitis B to prevent this infection


Mukomolov S.L., Mikhailov M.I.

Saint Petersburg Pasteur Research Institute of Epidemiology and Microbiology, Russian Inspectorate for the Protection of Consumer Rights and Human Welfare, Saint Petersburg; M.P. Chumakov Institute of Poliomyelitis and Viral Encephalitides, Russian Academy of Medical Sciences, Moscow
For the specific prevention of hepatitis B (HB), it is advisable to use purified HB virus surface antigen (HBsAg)-based vaccines to form active immunity and HB immunoglobulin (HBIG) containing the high concentrations of antibodies to anti-HBsAg (anti-HBs). Active/passive immunization that contemplates the simultaneous administration of HBIG and HB vaccine is a preferred variant of emergency prevention of HB. This approach should be applied when there is a high probability of percutaneous HB virus inoculation after prick with a blood-contaminated needle or another sharp instrument; after bite or another skin injury; when there is a high risk of transmission across the mucosae, for example when infected blood gets on the conjunctiva and other mucosae; there is a risk of sexual transmission during unprotected heterosexual or homosexual contact; there is a high risk of transmission from the virus-carrying mother (who is ill with chronic HB) to her neonatal baby; for the prevention of recurrent HB after liver transplantation with or without specific antiviral drugs, as well as in those who are unresponsive to HB vaccination if there has been a likely contact with HB virus.

About the Autors


Prof. Mukomolov Sergei Leonidovich, MD; Head, Laboratory of Viral Hepatitides and Department of Epidemiology, Saint Petersburg Pasteur Research Institute of Epidemiology and Microbiology, Russian Inspectorate for the Protection of Consumer Rights and Human Welfare
Address: 14, Mir St., Saint Petersburg 197101
Telephone: +7(812) 232-90-68
E-mail: s.mukomolov@mail.ru


Similar Articles


Бионика Медиа